SEC Filing Summary

Lucinda Warren, Chief Business Officer of Cue Biopharma, Inc., was granted 250,000 stock options on April 9, 2026. These options have an exercise price of $0.29 and will expire on April 8, 2036. The options vest over four years, with 25% vesting after the first year and the remainder vesting in equal semi-annual installments thereafter. The transaction is reported on Form 4 and indicates a direct ownership nature.